Abstract: A device generates a synthetic frame based on a plurality of source frames. The synthetic frame and a target frame corresponding to a same particular output time. For each block of the target frame, the device may determine, based on a comparison of the block of the target frame and a corresponding block of the synthetic frame, a weight for the block of the target frame. Furthermore, the device determines, based on the weight for the block of the target frame relative to a predetermined threshold, whether to change pixels of the block of the target frame to a fixed value. The device outputs data comprising a representation of the block of the target frame and the weight for the block of the target frame.

Abstract: A device obtains a plurality of original high-resolution frames and a low-resolution frame. The device generates, based on the plurality of original high-resolution frames, a first additional high-resolution frame. The first additional high-resolution frame and the low-resolution frame correspond to a same output time. The device generates a down-sampled frame by down-sampling the first additional higher-resolution frame. Additionally, the device determines, based on comparisons of blocks of the low-resolution frame and blocks of the down-sampled frame, a plurality of weights. The device generates an up-sampled frame by up-sampling the low-resolution frame. The device generates a second additional high-resolution frame based on a weighted average of the up-sampled frame and the first additional high-resolution frame. The weighted average is based on the plurality of weights.

Abstract: A device obtains a plurality of original high-resolution frames and a low-resolution frame. The device generates, based on the plurality of original high-resolution frames, a first additional high-resolution frame. The first additional high-resolution frame and the low-resolution frame correspond to a same output time. The device generates a down-sampled frame by down-sampling the first additional higher-resolution frame. Additionally, the device determines, based on comparisons of blocks of the low-resolution frame and blocks of the down-sampled frame, a plurality of weights. The device generates an up-sampled frame by up-sampling the low-resolution frame. The device generates a second additional high-resolution frame based on a weighted average of the up-sampled frame and the first additional high-resolution frame. The weighted average is based on the plurality of weights.

Abstract: Embodiments relate to performing data blending operations across multiple different data sets comprising data structures with columns and rows. Columns of data sets to be blended may be linked together. Filters may be applied to data sets before the data blend operation is performed to specify which columns to be displayed in a visualization at a client interface. A direct filter may be applied to one of the data sets to obtain a filtered resulting data set. Data elements of the filtered resulting data set can be identified that correspond to the linked columns of the data sets to be blended. The results of applying the direct filter may then be used as the filtering criteria for an indirect filter to filter a second data set. The results of applying the direct and indirect filters may then be combined together in the data blending operation.

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Abstract: Embodiments relate to performing data blending operations across multiple different data sets comprising data structures with columns and rows. Columns of data sets to be blended may be linked together. Filters may be applied to data sets before the data blend operation is performed to specify which columns to be displayed in a visualization at a client interface. A direct filter may be applied to one of the data sets to obtain a filtered resulting data set. Data elements of the filtered resulting data set can be identified that correspond to the linked columns of the data sets to be blended. The results of applying the direct filter may then be used as the filtering criteria for an indirect filter to filter a second data set. The results of applying the direct and indirect filters may then be combined together in the data blending operation.

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Abstract: Methods, systems, and computer-readable medium are provided for retinopathy evaluation. A retina image and a first plurality of user input controls representing a categories of features related to retinopathy evaluation, are displayed in a user interface. A selection of a first user input control corresponding to a first selected category of features is received. In response to receiving the selection, a second plurality of user input controls are displayed that represents a first set of features associated with the first selected category of features. A selection of a second user input control is received indicating a first feature appearing in the retina image. Findings are determined based on at least the first selected feature. Information related to a diagnosis is determined based on the one or more findings using the processor of the client mobile device, and the information related to the diagnosis is displayed.

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.

Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.

Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.